BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 43
- Registration Number
- NCT05547399
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 55
- Registration Number
- NCT05494762
- Locations
- 🇦🇺
Icon Cancer Centre Kurralta Park, Kurralta Park, South Australia, Australia
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 100
- Registration Number
- NCT05479994
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Institute of Hematology and Hospital of Blood Disease, Tianjin, Tianjin, China
🇨🇳The First Peoples Hospital of Kashgar, Kashgar, Xinjiang, China
Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 126
- Registration Number
- NCT05471843
- Locations
- 🇺🇸
Luminis Health Anne Arundel Medical Center, Annapolis, Maryland, United States
🇺🇸Dartmouth Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 96
- Registration Number
- NCT05461794
- Locations
- 🇨🇳
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05387668
- Locations
- 🇺🇸
PPD, Las Vegas, Nevada, United States
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 210
- Registration Number
- NCT05381909
- Locations
- 🇦🇺
Icon Cancer Centre South Brisbane, South Brisbane, Queensland, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
🇺🇸Banner Md Anderson Cancer Center, Gilbert, Arizona, United States
Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 8
- Registration Number
- NCT05373901
- Locations
- 🇨🇳
Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine, Shanghai, Shanghai, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳The Children's Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 127
- Registration Number
- NCT05294731
- Locations
- 🇨🇳
Xiangyang Central Hospital, Xiangyang, Hubei, China
🇨🇳The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 53
- Registration Number
- NCT05267054
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Hospital, Beijing, Beijing, China